Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Anti-Inflammatory and Cytoprotective Reduces systemic inflammation markers
To view or add a comment, sign in For years, obesity was viewed as a personal failure instead of a chronic disease
Always consult a licensed healthcare provider before starting any supplement, diet, exercise program, or wellness routine-especially if you are pregnant, nursing, taking prescription medication, or managing a chronic health condition
Scientific References Xultophy 100 units/mL + 3.6 mg/mL solution for injection - Summary of Product Characteristics
In cardiovascular outcome trials (CVOTs) such as Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients (EMPA-REG OUTCOME), CANagliflozin cardioVascular Assessment Study (CANVAS) and The Dapagliflozin Effect on Cardiovascular EventsThrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) [6], they reduced the onset and progression of DKD, which was confirmed in the dedicated kidney trial The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), which showed a canagliflozin-induced risk reduction for ESKD in people with DKD by 32% [7]
